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Background: Early diagnosis and monitoring of disease activity are essential in cystic ﬁbrosis (CF) and primary ciliary dyskinesia (PCD). We
aimed to establish exhaled molecular proﬁles as the ﬁrst step in assessing the potential of breath analysis.
Methods: Exhaled breath was analyzed by electronic nose in 25 children with CF, 25 with PCD and 23 controls. Principle component reduction
and canonical discriminant analysis were used to construct internally cross-validated ROC curves.
Results: CF and PCD patients had signiﬁcantly different breath proﬁles when compared to healthy controls (CF: sensitivity 84%, speciﬁcity 65%;
PCD: sensitivity 88%, speciﬁcity 52%) and from each other (sensitivity 84%, speciﬁcity 60%). Patients with and without exacerbations had
signiﬁcantly different breath proﬁles (CF: sensitivity 89%, speciﬁcity 56%; PCD: sensitivity 100%, speciﬁcity 90%).
Conclusion: Exhaled molecular proﬁles signiﬁcantly differ between patients with CF, PCD and controls. The eNose may have potential in disease
monitoring based on the inﬂuence of exacerbations on the VOC-proﬁle.
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Cystic fibrosis (CF) and primary ciliary dyskinesia (PCD)
have a major impact on health and quality of life. Early diagnosis,
frequent monitoring and vigorous treatment of respiratory
infections are key to preserving lung function [1,2]. For CF
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http://dx.doi.org/10.1016/j.jcf.2012.12.010remains challenging to diagnose as a single gold standard is
lacking [1,3]. Guidelines for the management of mucociliary
diseases are based on the monitoring of symptoms [1,4].
Unfortunately, the correlation between clinical symptoms and
the underlying disease activity is generally poor and can only be
established by invasive procedures [5]. Infection and inflamma-
tion may be present before clinical parameters change. Therefore,
early detection and treatment of respiratory pathogens and
exacerbations may improve clinical outcome. This creates the
need for non-invasive methods in the monitoring of disease
activity in CF and PCD.
Analysis of volatile biomarkers in exhaled breath has shown
to provide an attractive method to monitor both infection [6]
and inflammation [7–9]. These Volatile Organic Compounds
(VOCs) are likely to originate from local and systemic metabolicby Elsevier B.V. All rights reserved.
455T. Paff et al. / Journal of Cystic Fibrosis 12 (2013) 454–460processes reflecting underlying disease processes. Analysis of
individual volatiles by Gas Chromatography–Mass Spectrometry
(GC–MS) and measurement of nasal nitric oxide illustrated that
concentrations of specific volatiles differ between CF and/or
PCD patients and healthy controls [10,11]. While GC–MS is an
essential technique to link individual components to pathophys-
iological mechanisms its clinical applicability is hampered by
the need for complex laboratory techniques and highly trained
personnel. Alternatively, electronic nose (eNose) technology
comprises arrays of promiscuous sensors interacting with the
exhaled volatile mixture in its entirety, providing a so-called
‘breathprint’ by using pattern-recognition algorithms [12].
Biomedical application of eNoses is emerging [13] and various
studies have demonstrated the value of this technology in the
discrimination of patients with asthma [14,15], COPD [8,14,15],
lung cancer [16,17] and ventilator-associated pneumonia [18].
For patients with CF and PCD exhaled breath analysis by
electronic nose may allow both early screening and frequent
monitoring, because the technique is portable, low cost and
provides immediate results. According to STARD guidelines [19],
the essential first step to assess this in CF and PCD is to establish
exhaled volatile profiles that discriminate a priori defined disease
entities. In this study we therefore hypothesized that patients with
cystic fibrosis, primary ciliary dyskinesia and healthy controls
have significantly different exhaled molecular profiles as deter-
mined by electronic nose. Furthermore we aim to study patients
without an exacerbation to assess its potential influence on
exhaled breath profiles. The secondary goal of this study was to
examine whether significantly different breath profiles could be
identified in patients with and without pulmonary exacerbations.
2. Methods
2.1. Design
This study was designed as a cross-sectional case–control
study. All patients performed a single study visit during which
exhaled breath was analyzed and sputum or cough swabs
were cultured. Spirometry was performed in patients six years
and older by a trained lung function technician according to
ATS/ERS guidelines [20].
2.2. Subjects
Children aged between 6 months and 18 years were
included. By only including children we aimed to investigate
CF and PCD patients with relatively limited concomitant
infections in their airways compared to adult patients. Patients
were recruited during outpatient clinics of the VU University
Medical Center Amsterdam, The Netherlands, between August
2011 and November 2011. Diagnosis of CF was based on
clinical symptoms in combination with an abnormal sweat test
(chlorideN60 mmol/l) and/or identification of mutations in
both alleles of the CFTR-gene [21]. PCD diagnosis was based
on a combination of clinical symptoms, evaluation of ciliary
beat frequency and pattern by high-resolution, high-speed
video microscopy and by transmission electron microscopyof ciliary ultrastructure as recommended by the European
Respiratory Society Task Force consensus statement [1].
Furthermore, ciliary motility was also evaluated after cell
culture to exclude secondary ciliary dyskinesia [22]. The
presence of a pulmonary exacerbation in CF and PCD patients
was determined after patients completed the study visit and was
defined as the need to start additional antibiotic treatment as a
consequence of a recent change in at least two of the following
clinical parameters: change in sputum volume or color,
increased cough, increased dyspnea, increased malaise, fatigue
or lethargy, temperature over 38°, anorexia or weight loss,
change in sinus discharge, change in physical findings on
examination, decrease in pulmonary function by 10% or more
and radiographic changes. This was done according to national
CBO guidelines, based on internationally accepted criteria
[5,23,24]. Healthy children were recruited during orthopedic
outpatient clinics of the VU University Medical Center and the
Academic Medical Center Amsterdam, The Netherlands. These
two academic centers are situated within 10 km of each other
and share the same patient population. Children were excluded
in case of any pulmonary, inflammatory or metabolic disease.
The study was approved by the Medical Ethical Committee of
the participating centers. Written informed consent was
obtained from parents and patients between 12 and 18 years.
The study was registered in the Netherlands Trial Register,
www.trialregister.nl under NTR 2847.
3. Measurements
3.1. Breath collection
Exhaled breath was collected using a modified spacer
(Babyhaler, GlaxoSmithKline) with reverse valve system allowing
tidal inspiration through a face mask and inspiratory VOC filter
(A2, North Safety, Middelburg, The Netherlands) and tidal
expiration into the spacer. The VOC filter minimizes the influence
of environmental VOCs on the breath profile as a potential source
of bias. The spacer was connected to the electronic nose during
sampling for direct sample analysis during tidal breathing.
3.2. Electronic nose
We used a carbon black polymer based Cyranose 320
electronic nose (Smiths Detection, Pasadena, CA, USA). VOCs
interact with the array of 32 polymer nanosensors to induce a
fully reversible change in electrical resistance. The changes in
resistance of all 32 sensors provide the raw data of the eNose and
were combined by pattern recognition analysis into a so-called
breathprint. This allows simultaneous analysis of the entire VOC
profile instead of analyzing individual sensors which would only
represent a limited fraction of the measured volatiles.
3.3. Statistical analysis
SPSS (version 16.0) was used for data analysis. Principal
component reduction was used to capture the variance of
the original breathprint into a set of orthogonal principal
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dataset to minimize the risk of overfitting [25]. Discriminating
PCs were selected by unpaired t-test and subsequently used in a
canonical discriminant analysis. The discriminant functions
were used to construct a receiver operator characteristic (ROC)
curve. The area under the curve (AUC) and optimum single
spot test sensitivity and specificity were determined. This data
was internally cross-validated by a bootstrapping procedure to
minimize the risk of false positive findings according to current
standards [25]. The current sample size was based on previous
studies employing electronic noses in discriminating asthma
[14,15], COPD [15] and lung cancer [16] because no previous
studies in CF and PCD were available.4. Results
Seventy-three subjects participated in this study, including
25 patients with CF (median age (yr), IQR, 11.4, 7.7–17.9), 25
patients with PCD (10.7, 7.1–14.5) and 23 healthy subjects
(9.3, 5.4–12.6). The subject characteristics of the three groups
are described in Table 1. Median age and sex did not
significantly differ between healthy controls recruited from
the two outpatient clinics. Nine CF patients (36%) and 4 PCD
patients (17%) had a pulmonary exacerbation. The percentage
of positive sputum and cough swab cultures did not differ
between patients with CF (16 out of 23 cultures) and PCD
(8 out of 18 cultures). The presence of Staphylococcus aureus
was significantly higher in cultures of CF patients as compared
to cultures of PCD patients (p=0.004). Haemophilus influenzae
occurred more frequently in cultures of PCD patients as
compared to cultures of CF patients (p=0.002). No other
significant differences in subject characteristics were found
between CF and PCD patients.Table 1
Clinical characteristics of the study population.
Cystic fibrosis
Subjects (n) 25
Age (years) a 11.4 [7.7–17.9]
Male (n/total) 10/25
Best FEV1 in past year (% predicted)
a 92.0[81.5–111.0]
Best FVC in past year (% predicted) a 99.0 [88.0–116.0]
Pulmonary exacerbation (n/total) 9/25
Positive bacterial cultures (n/total) 15/22
S. aureus (n) 13 b
Pseudomonas spp. 5
H. influenzae 1 c
S. maltophilia 1
M. avium 1
A. denitrificans 1
M. catarrhalis 0
S. pneumoniae 0
Other 1
N: number; n/a: not available; FEV1: Forced expiratory volume in 1 s, pre-bronchod
aureus; Pseudomonas spp: Pseudomonas species; H. influenzae: Haemophilus influe
avium; A. denitrificans: Achromobacter denitrificans; M. catarrhalis: Moraxella cat
a Data are presented as median and interquartile range.
b p=0.004 as compared to patients with PCD.
c p=0.002 as compared to PCD.Breathprints from patients with CF (p=0.0004) and with
PCD (p=0.0001) significantly differed from healthy subjects
(Figs. 1a, 2a). The area under the receiver operator characteristic
(ROC) curve (AUC) after internal cross-validation reached
0.76 (95% CI 0.62–0.90, sensitivity 84%, specificity 65%) and
0.80 (95% CI 0.67–0.93, sensitivity 88%, specificity 52%),
respectively (Figs. 1b, 2b). Additionally, exhaled breath profiles
differed significantly between patients with CF and PCD
(p=0.001) (Fig. 3a). ROC analysis resulted in an AUC of 0.77
(95% CI 0.63–0.91, sensitivity 84%, specificity 60%) (Fig. 3b).
CF (n=16) and PCD (n=19) breath profiles still differed
significantly from one another after omitting breath profiles
from patients with a pulmonary exacerbation (p=0.001). The
AUC reached 0.77 (95% CI 0.60–0.95) and sensitivity and
specificity increased to 95% and 63%, respectively. Detailed
test characteristics for the diagnostic models are presented in
Table 2.
VOC profiles of CF patients (p=0.01) as well as PCD patients
(p=0.01) with and without a pulmonary exacerbation differed
significantly. ROC analysis resulted in an AUC of 0.76 (95% CI
0.58–0.95, sensitivity 89%, specificity 56%) and 0.90 (95% CI
0.76–1.00, sensitivity 100%, specificity 90%), respectively.
5. Discussion
Our study shows that CF and PCD patients have signif-
icantly different exhaled breath molecular profiles compared to
healthy subjects as determined by electronic nose. Furthermore,
we observed that CF and PCD have significantly different VOC
profiles allowing separation with reasonable sensitivity but
rather limited specificity. In addition, we observed that VOC
profiles differed significantly depending on the presence of a
pulmonary exacerbation. Our results suggest that exhaled
breath analysis may have diagnostic and monitoring potentialPrimary Ciliary dyskinesia Healthy subjects
25 23
10.7 [7.1–14.5] 9.3 [5.4–12.6]
14/25 14/23
104.0 [80.5–109.8] n/a
110.5 [97.0–119.0] n/a
4/23 n/a
8/18 n/a
2 n/a
1 n/a
6 n/a
0 n/a
0 n/a
0 n/a
2 n/a
2 n/a
5 n/a
ilator; FVC: forced vital capacity, pre-bronchodilator; S. aureus: Staphylococcus
nzae; S. maltophilia: Stenotrophomonas maltophilia;M. avium:Mycobacterium
arrhalis; S. Pneumoniae: Streptococcus pneumoniae.
a b
Fig. 1. Discrimination of CF patients vs. healthy subjects. (a) Two-dimensional principal component plot showing the discrimination of breathprints between patients
with CF (circles) and healthy controls (triangles) along two discriminative principal components. p=0.0004. (b) Receiver operator characteristic (ROC) curve with
line of identity of the breathprint discriminant function for the discrimination of CF patients and healthy controls (AUC 0.76).
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tion and validation.
To our knowledge this is the first study using eNose tech-
nology in CF and PCD. Previously, Robroeks et al. identified
individual VOCs related to CF by GC–MS analysis of exhaled
breath [10]. Our findings extend these results by showing that
children with CF have significantly different total VOC profiles
compared to healthy subjects. The other novelty of this study wasa b
Fig. 2. Discrimination of PCD patients vs. healthy subjects. (a) Two-dimensional
patients with PCD (diamonds) and healthy controls (triangles) along two discriminati
curve with line of identity of the breathprint discriminant function for the discriminto show that the exhaled marker profile of PCD was significantly
different from patients with CF and controls. Compared to nasal
nitric oxide measurement in PCD the eNose has lower sensitivity
and specificity for detecting PCD [11]. As with the eNose,
although to a lower extent, nasal nitric oxide is not specific for
PCD and shows overlap with CF, nasal polyps, chronic sinusitis
and diffuse pan-bronchiolitis. Even though further studies are
necessary eNose technique could be complementary to nasalprincipal component plot showing the discrimination of breathprints between
ve principal components. p=0.0001. (b) Receiver operator characteristic (ROC)
ation of PCD patients and healthy controls (AUC 0.80).
a b
Fig. 3. Discrimination of CF patients vs. PCD patients. (a) Two-dimensional principal component plot showing the discrimination of breathprints between patients
with CF (circles) and PCD (diamonds) along two discriminative principal components. p=0.001. (b) Receiver operator characteristic (ROC) curve with line of
identity of the breathprint discriminant function for the discrimination of CF patients and PCD patients (AUC 0.77).
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perform across all ages and may require less rigorous control of
measurement circumstances.
In the present study, all included patients were well
characterized according to internationally accepted guidelines,
were recruited by the same operator and originated from the
same outpatient clinic [1,21]. Control subjects were recruited
from two outpatient clinics which were located in the same
geographical area sharing the same patient population. Sub-
analysis showed that there was no significant difference
between exhaled breath profiles between the healthy controls
recruited at the different clinics (p=0.16). We aimed to study
children in order to minimize the number of concomitant
respiratory infections as compared to adult patients, thereby
reducing the potential influence of VOCs derived from
pathogens on the study outcome. However, in 16 out of 23
CF patients and 8 out of 18 PCD patients, pathogens were still
detected by culturing. It should also be noted that negative
culture results do not exclude the presence of airway pathogens,
as various recent microbiome studies in CF have demonstrated
[26]. Furthermore the number of positive bacterial culturesTable 2
Test characteristics of the receiver operator characteristic (ROC) curves for discrimin
patients with and without a pulmonary exacerbation, by exhaled breath analysis.
N AUC
CF vs. healthy subjects 25 vs. 23 0.76
PCD vs. healthy subjects 25 vs. 23 0.80
CF vs. PCD 25 vs. 25 0.77
CF pulmonary exacerbation vs. stable disease 9 vs. 16 0.76
PCD pulmonary exacerbation vs. stable disease 4 vs. 19 0.90
CF stable disease vs. PCD stable disease 16 vs. 19 0.77
Test characteristics of the receiver operator characteristic (ROC) curves for the discr
PCD patients vs. CF patients and patients with and without a pulmonary exacer
dyskinesia; vs.: versus; N: number; AUC: area under the curve; 95% CI: 95% confibetween CF and PCD patients in this study did not differ
although the incidence of S. aureus and H. influenzae did. The
presence of pathogens may therefore be a potential source of
bias in the discrimination of CF/PCD from healthy controls. In
a post-hoc analysis there was no significant difference between
breath profiles in the presence or absence of an infection
(p=0.33). The exact influence of pathogens on the VOC profile
is however difficult to determine because the VOCs resulting
from these infections are a combination of VOCs produced by
the pathogen itself and the host response to that pathogen. A
way of determining VOCs produced by individual pathogens is
by studying the production of VOCs from in vitro cultures by
chemical analytical techniques such as GC–MS [13]. This
however reaches beyond the scope of the current paper.
Even though CF and PCD are both characterized by chronic
airway infection and neutrophilic inflammation, they originate
from different pathophysiological [5,27] mechanisms. It is likely
that distinct inflammatory and metabolic processes generate partly
different metabolites, explaining the different VOC mixtures
in exhaled breath for both CF, PCD and healthy subjects [8].
Previous studies have shown that sputum of patients withation of CF patients, PCD patients and healthy subjects and for discrimination of
95% CI p-Value Sens (%) Spec (%)
0.62–0.90 0.002 84 65
0.67–0.93 b0.001 88 52
0.63–0.91 0.001 84 60
0.58–0.95 0.031 89 56
0.76–1.00 0.015 100 90
0.60–0.95 0.006 95 63
imination of CF patients vs. healthy subjects, PCD patients vs. healthy subjects,
bation, by exhaled breath analysis. CF: cystic fibrosis; PCD: primary ciliary
dence interval of the area under the curve; Sens: sensitivity; Spec: specificity.
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concentration, a trend towards a lower DNA concentration and
lower levels of proteolytic enzymes as compared to subjects with
CF, possibly reflecting differences in pathophysiological path-
ways [28,29]. The significant differences between VOC profiles
of these two mucociliary clearance diseases may thus very well
originate from partially distinct inflammatory processes. It will
require detailed characterization of individual VOCs by GC–MS
to establish the molecular compounds driving this signal. The
latter is complementary to probabilistic diagnostic assessment by
eNose.
Our study supports the notion that some of the discriminat-
ing VOCs are related to the host response by showing that CF
and PCD breath profiles could be differentiated with slightly
improved test sensitivity and specificity when patients with a
pulmonary exacerbation were omitted. This suggests that
disease specific VOCs for PCD and CF may exist. Furthermore
this suggests that inflammatory changes can be detected by
exhaled breath analysis potentially allowing monitoring of
disease activity. It is important to investigate this in detail in a
study specifically designed for this purpose as the current
study was not sufficiently powered to address these questions.
Therefore, the latter results are merely hypothesis-generating,
requiring further study in a larger cohort.
Comparing gold standard diagnostic groups represents the first
step of implementing a novel diagnostic technique into clinical
practice according to the STARD guidelines [19]. Even though
the currently observed sensitivities are promising, the specificities
of the present analysis were still limited. We used bootstrapping
procedures to minimize the possibility of false positive results
which may occur when analyzing multivariate data [25].
Given the relatively high sensitivity for PCD in the present
study, it can be inferred that breath analysis may have additional
value in the initial diagnostic work-up of PCD. Particularly,
since PCD is likely to be under diagnosed due to the lack of a
single gold standard, ambiguous interpretation of diagnostic tests
and the partial overlap of symptoms from healthy children
suffering from recurrent respiratory tract infections [1,30].
The observation that exhaled breath profiles differ signifi-
cantly depending on the absence or presence of a pulmonary
exacerbation suggests that the eNose may be a tool for non-
invasive monitoring of disease activity in both CF and PCD. As
recurrent respiratory infections and inflammation result in
progressive lung damage, early detection and treatment are of
major importance to improve clinical outcome in these patients.
Future longitudinal studies should clarify whether VOC profiling
of exhaled breath in CF and PCD patients may add to earlier
identification and treatment of respiratory infections as es-
tablished by quantitative PCR and microbiome technologies.
Furthermore the technological advances of breath analysis
techniques are likely to increase its value for CF and PCD. The
eNose device used in this study is based on the interaction of
polymers with the VOCs inducing a resistance change. Many
other techniques exist such as quartz microbalance sensors,
metal oxide sensors and optical sensors. It's important to study
the value of these sensors in the discrimination of CF and PCD
in more detail.New studies employing chemical analytical techniques such
as GC–MS allow the identification of individual VOCs and may
aid to connect VOCs to specific disease processes. Importantly
this can also facilitate the selection of the most suitable eNose
sensors for the desired application and novel development of
disease tailored sensors. This may greatly improve the clinical
applicability of exhaled breath analysis by eNose.
In conclusion, our study showed that CF, PCD, healthy
children and patients with and without pulmonary exacerbations
have significantly different exhaled breath profiles as determined
by an electronic nose. Therefore, after optimization and vali-
dation, exhaled breath analysis by eNose may eventually qualify
as a non-invasive and easy to use tool in the monitoring of CF and
PCD in clinical practice.Conﬂict of interest statement
None of the authors have conflicts of interest to disclose.Acknowledgments
This study was supported by the “Stichting PCD
Belangengroep”. They had no involvement in the study
design, the collection and analysis of data, writing the
manuscript or the decision to submit the manuscript.References
[1] Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, et al.
Primary ciliary dyskinesia: a consensus statement on diagnostic and
treatment approaches in children. Eur Respir J Dec. 2009;34(6):1264–76.
[2] Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort
of primary ciliary dyskinesia. Eur Respir J Oct. 1 1997;10(10):2376–9.
[3] Strippoli M, Frischer T, Barbato A, Snijders D, Maurer E, Lucas JSA,
et al. Management of primary ciliary dyskinesia in European children:
recommendations and clinical practice. Eur Respir J 2012;39(6):1482–91.
[4] Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn
RJ, et al. Pulmonary perspective cystic fibrosis pulmonary guidelines:
treatment of pulmonary exacerbations. Am J Respir Crit Care Med
2009;180:802–8.
[5] Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of
pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med Oct.
15 2003;168(8):918–51.
[6] Zhu J, Bean HD, Kuo YM, Hill JE. Fast detection of volatile organic
compounds from bacterial cultures by secondary electrospray ionization–
mass spectrometry. J Clin Microbiol 2010;48(12):4426–31.
[7] Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics:
biomarkers of diseases. Biomed Chromatogr 2007;566:553–66.
[8] Fens N, Nijs SBD, Peters S, Dekker T, Knobel HH, Vink TJ, et al.
Exhaled air molecular profiling in relation to inflammatory subtype and
activity in COPD. Eur Respir J 2011;38(6):1301–9.
[9] Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, et al.
Non-invasive phenotyping using exhaled volatile organic compounds in
asthma. Thorax 2011;66(9):804–9.
[10] Robroeks CMHHT, van Berkel JJBN, Dallinga JW, Jöbsis Q, Zimmermann
LJI, Hendriks HJE, et al. Metabolomics of volatile organic compounds in
cystic fibrosis patients and controls. Pediatr Res Jul. 2010;68(1):75–80.
[11] Walker WT, Jackson CL, Lackie PM, Hogg C, Lucas JS. Nitric oxide in
primary ciliary dyskinesia. Eur Respir J Oct. 2012;40(4):1024–32.
[12] Röck F, Barsan N, Weimar U. Electronic nose: current status and future
trends. Chem Rev 2008;108(2):705–25.
460 T. Paff et al. / Journal of Cystic Fibrosis 12 (2013) 454–460[13] Wilson AD, Baietto M. Advances in electronic-nose technologies
developed for biomedical applications. Sensors Jan. 2011;11(1):1105–76.
[14] Fens N, Zwinderman AH, van der Schee MP. Exhaled breath profiling
enables discrimination of chronic obstructive pulmonary disease and
asthma. Am J Respir Crit Care Med Dec. 1 2009;180(11):1076–82.
[15] Fens N, Roldaan AC, van der Schee MP, Boksem RJ, Zwinderman AH,
Bel EH, et al. External validation of exhaled breath profiling using an
electronic nose in the discrimination of asthma with fixed airways
obstruction and chronic obstructive pulmonary disease. Clin Exp Allergy
Jul. 7 2011;41(10):1371–8.
[16] Dragonieri S, Annema JT, Schot R, van der Schee MP, Spanevello A,
Carratú P, et al. Lung cancer an electronic nose in the discrimination of
patients with non-small cell lung cancer and COPD. Lung Cancer
2009;64:166–70.
[17] Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach J-I. Ion
mobility spectrometry for the detection of volatile organic compounds in
exhaled breath of patients with lung cancer: results of a pilot study. Thorax
Sep. 2009;64(9):744–8.
[18] Hanson C, Thaler ER. Electronic nose prediction of a clinical pneumonia
score: biosensors and microbes. Anesthesiology 2005;1:63–8.
[19] Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
et al. The STARD statement for reporting studies of diagnostic accuracy:
explanation and elaboration. Ann Intern Med 2003;138(1):1–12.
[20] Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A,
et al. Standardisation of spirometry. Eur Respir J 2005;26(2):319–38.
[21] Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellini C, Cutting
GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through
older adults: cystic fibrosis foundation consensus report. J Pediatr
2008;153(2):S4–S14.[22] Hirst Ra, Rutman A, Williams G, O'Callaghan C. Ciliated air–liquid
cultures as an aid to diagnostic testing of primary ciliary dyskinesia. Chest
Dec. 2010;138(6):1441–7.
[23] Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Diagnostiek
en Behandeling Cystic Fibrosis; 2009.
[24] Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, et al.
Pulmonary exacerbation: towards a definition for use in clinical trials.
Report from the EuroCareCF Working Group on outcome parameters in
clinical trials. J Cyst Fibros Jun. 2011;10(Suppl. 2):S79–81.
[25] Broadhurst DI, Kell DB. Statistical strategies for avoiding false discoveries
in metabolomics and related experiments. Metabolomics Nov. 28 2006;2(4):
171–96.
[26] Sibley CD, Grinwis ME, Field TR, Eshaghurshan CS, Faria MM, Dowd
SE, et al. Culture enriched molecular profiling of the cystic fibrosis airway
microbiome. PLoS One Jan. 2011;6(7):e22702.
[27] Zariwala Ma, Knowles MR, Omran H. Genetic defects in ciliary structure
and function. Annu Rev Physiol Jan. 2007;69:423–50.
[28] Bush A, Payne D, Pike S, Jenkins G, Henke MO, Rubin BK. Mucus
properties in children with primary ciliary dyskinesia: comparison with
cystic fibrosis. Chest Jan. 2006;129(1):118–23.
[29] Mackerness KJ, Jose PJ, Bush A. Differences in airway inflammation in
cystic fibrosis and primary ciliary dyskinesia. Pediatr Asthma Allergy
Immunol 2009;22(4):163–8.
[30] Kuehni CE, Frischer T, Strippoli M-PF, Maurer E, Bush A, Nielsen KG,
et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in
European children. Eur Respir J Dec. 2010;36(6):1248–58.
